Cargando…

A randomised controlled trial to evaluate a medication monitoring system for TB treatment

BACKGROUND : Adherence to TB treatment and therefore treatment success could be improved using digital adherence technology. OBJECTIVE : To evaluate the effectiveness of a medication event reminder monitor system (MERM) on treatment success and treatment adherence in patients with drug-susceptible p...

Descripción completa

Detalles Bibliográficos
Autores principales: Acosta, J., Flores, P., Alarcón, M., Grande-Ortiz, M., Moreno-Exebio, L., Puyen, Z. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Union Against Tuberculosis and Lung Disease 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8734191/
https://www.ncbi.nlm.nih.gov/pubmed/34969428
http://dx.doi.org/10.5588/ijtld.21.0373
_version_ 1784627964817702912
author Acosta, J.
Flores, P.
Alarcón, M.
Grande-Ortiz, M.
Moreno-Exebio, L.
Puyen, Z. M.
author_facet Acosta, J.
Flores, P.
Alarcón, M.
Grande-Ortiz, M.
Moreno-Exebio, L.
Puyen, Z. M.
author_sort Acosta, J.
collection PubMed
description BACKGROUND : Adherence to TB treatment and therefore treatment success could be improved using digital adherence technology. OBJECTIVE : To evaluate the effectiveness of a medication event reminder monitor system (MERM) on treatment success and treatment adherence in patients with drug-susceptible pulmonary TB in Perú. METHODS : This was an experimental, randomised, open-label, controlled study conducted among patients in the second phase of TB treatment. The intervention group received their medications through MERM with the support of a treatment monitor, whereas the control group used the usual strategy. Participants were followed until they completed the 54 doses of the second phase of treatment. RESULTS : The study included 53 patients in each group; four in the intervention group withdrew from the study. Treatment success was significantly more frequent in the MERM group (RR 1.15, 95% CI 1.02–1.30; P = 0.0322). There was no significant difference in the adherence outcomes; however, the percentage of patients who missed at least one dose and patients with more than 10% of total doses missed were lower in the intervention group. CONCLUSION : The use of MERM in the second phase of treatment showed a significant improvement in the treatment success rate in patients with drug-susceptible pulmonary TB.
format Online
Article
Text
id pubmed-8734191
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher International Union Against Tuberculosis and Lung Disease
record_format MEDLINE/PubMed
spelling pubmed-87341912022-01-07 A randomised controlled trial to evaluate a medication monitoring system for TB treatment Acosta, J. Flores, P. Alarcón, M. Grande-Ortiz, M. Moreno-Exebio, L. Puyen, Z. M. Int J Tuberc Lung Dis Original Articles BACKGROUND : Adherence to TB treatment and therefore treatment success could be improved using digital adherence technology. OBJECTIVE : To evaluate the effectiveness of a medication event reminder monitor system (MERM) on treatment success and treatment adherence in patients with drug-susceptible pulmonary TB in Perú. METHODS : This was an experimental, randomised, open-label, controlled study conducted among patients in the second phase of TB treatment. The intervention group received their medications through MERM with the support of a treatment monitor, whereas the control group used the usual strategy. Participants were followed until they completed the 54 doses of the second phase of treatment. RESULTS : The study included 53 patients in each group; four in the intervention group withdrew from the study. Treatment success was significantly more frequent in the MERM group (RR 1.15, 95% CI 1.02–1.30; P = 0.0322). There was no significant difference in the adherence outcomes; however, the percentage of patients who missed at least one dose and patients with more than 10% of total doses missed were lower in the intervention group. CONCLUSION : The use of MERM in the second phase of treatment showed a significant improvement in the treatment success rate in patients with drug-susceptible pulmonary TB. International Union Against Tuberculosis and Lung Disease 2022-01-01 2022-01-01 /pmc/articles/PMC8734191/ /pubmed/34969428 http://dx.doi.org/10.5588/ijtld.21.0373 Text en © 2022 The Union https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Licence (http://creativecommons.org/licenses/by/4.0 (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.
spellingShingle Original Articles
Acosta, J.
Flores, P.
Alarcón, M.
Grande-Ortiz, M.
Moreno-Exebio, L.
Puyen, Z. M.
A randomised controlled trial to evaluate a medication monitoring system for TB treatment
title A randomised controlled trial to evaluate a medication monitoring system for TB treatment
title_full A randomised controlled trial to evaluate a medication monitoring system for TB treatment
title_fullStr A randomised controlled trial to evaluate a medication monitoring system for TB treatment
title_full_unstemmed A randomised controlled trial to evaluate a medication monitoring system for TB treatment
title_short A randomised controlled trial to evaluate a medication monitoring system for TB treatment
title_sort randomised controlled trial to evaluate a medication monitoring system for tb treatment
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8734191/
https://www.ncbi.nlm.nih.gov/pubmed/34969428
http://dx.doi.org/10.5588/ijtld.21.0373
work_keys_str_mv AT acostaj arandomisedcontrolledtrialtoevaluateamedicationmonitoringsystemfortbtreatment
AT floresp arandomisedcontrolledtrialtoevaluateamedicationmonitoringsystemfortbtreatment
AT alarconm arandomisedcontrolledtrialtoevaluateamedicationmonitoringsystemfortbtreatment
AT grandeortizm arandomisedcontrolledtrialtoevaluateamedicationmonitoringsystemfortbtreatment
AT morenoexebiol arandomisedcontrolledtrialtoevaluateamedicationmonitoringsystemfortbtreatment
AT puyenzm arandomisedcontrolledtrialtoevaluateamedicationmonitoringsystemfortbtreatment
AT acostaj randomisedcontrolledtrialtoevaluateamedicationmonitoringsystemfortbtreatment
AT floresp randomisedcontrolledtrialtoevaluateamedicationmonitoringsystemfortbtreatment
AT alarconm randomisedcontrolledtrialtoevaluateamedicationmonitoringsystemfortbtreatment
AT grandeortizm randomisedcontrolledtrialtoevaluateamedicationmonitoringsystemfortbtreatment
AT morenoexebiol randomisedcontrolledtrialtoevaluateamedicationmonitoringsystemfortbtreatment
AT puyenzm randomisedcontrolledtrialtoevaluateamedicationmonitoringsystemfortbtreatment